The BROADEN study measured HPV-attributable fractions in head and neck cancers in France, Germany, Italy, Portugal, Spain, China and Japan. Tissue from 6,043 patients at 88 hospitals was centrally tested for HPV-DNA, HPV-E6*I mRNA and p16INK4a. Oropharyngeal cancer required two of three positive tests; other sites required both DNA and mRNA positivity. In oropharyngeal cancer the fraction rose from 0% to 20.0% in Portugal and from 44.2% to 51.7% in Japan. Increases were significant in all countries except China and Japan; other sites stayed at 5% or less. The study is retrospective and uses hospital samples rather than population registries.
Why it is interesting: Gives like-for-like HPV attribution across seven countries using one central testing protocol. Shows the rise is confined to the oropharynx, with other head and neck sites flat.
Abstract — the authors' own words, CC BY
Background
The incidence of human papillomavirus (HPV)-driven oropharyngeal cancer (OPC) is increasing in several Western countries, but this trend is less well understood in other geographical regions and for other head and neck cancers (HNC). The BROADEN (absolute BuRden Of HPV relAteD hEad and Neck) study assessed HPV-attributable fractions (HPV-AFs) of HNC including OPC in France, Germany, Italy, Portugal, Spain, China, and Japan over a 10-year period. Methods
This retrospective study included patients diagnosed with HNC (oropharynx, oral cavity, nasopharynx, hypopharynx, and larynx cancer) in two time periods, 2008-2009 and 2018-2019. Formalin-fixed tissue samples were centrally tested for HPV-DNA, HPV-E6*I mRNA, and p16INK4a immunohistochemistry. HPV attributability required positive results in two of the three tests for OPC, and both HPV-DNA and HPV-E6*I mRNA positivity for other HNC. Results
Among 6043 patients from 88 hospitals, the HPV-AF in OPC shown an increasing trend across all countries, with an HPV-AF ranging between 0% in Portugal and 44.2% in Japan in 2008-2009, and 20.0% and 51.7%, respectively, in 2018-2019. The increasing trend reached the statistical significance at 0.05 in all countries except China and Japan. Japan had the highest HPV-AF in 2008-2009. Other HNC showed lower HPV-AF (≤5%) with no time trends. Conclusion
BROADEN is the first and largest study to date to investigate HPV causality and its time trends across five HNCs in seven countries. These results support the understanding of time trends and geographic variation in HPV-AF and are essential for global HNC prevention and treatment.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.
Other drivers in Health today
-
Cancer
Where is cancer incidence rising and falling, what screening and new tests find earlier, and what treatment has done to survival.
8 this week -
Obesity, diabetes and GLP-1
Are obesity and diabetes still rising, what behavioural change and public policy do, and what difference do GLP-1s and other similar drugs make.
10 this week -
Heart and stroke
Whether deaths from heart disease and stroke have stopped falling, what is found earlier, what treatment and prevention do now, and what the deaths say.
4 this week -
Mental health
Deaths by suicide, the life expectancy gap in severe mental illness, and the physical disease that follows it: what mental illness costs in lives.
1 this week -
Dementia
Whether dementia is becoming more or less common, what is now found, what treatment and prevention do, and what the deaths say.
4 this week -
Frailty and multimorbidity
Whether the years added after 85 are healthy ones, how frailty and multiple conditions are measured, and where the data run out.
2 this week
